Qulipta Disease Interactions
There is 1 disease interaction with Qulipta (atogepant).
Atogepant (applies to Qulipta) hepatic impairment
Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Atogepant should be avoided in patients with severe hepatic impairment. For patients with mild (Child-Pugh Class A), moderate (Child-Pugh Class B), or severe hepatic impairment (Child-Pugh Class C), total atogepant exposure increased by 24%, 15%, and 38%, respectively. During clinical trials, cases of elevated transaminase levels to over 3 times the upper limit of normal were temporally associated with atogepant use; these cases were asymptomatic and resolved within 8 weeks of discontinuation.
References
- "Product Information. Qulipta (atogepant)." AbbVie US LLC (2021):
Qulipta drug interactions
There are 172 drug interactions with Qulipta (atogepant).
More about Qulipta (atogepant)
- Qulipta consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (55)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: CGRP inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.